Compounds > diltiazem

Page last updated: 2024-08-23

diltiazem and raloxifene

diltiazem has been researched along with raloxifene in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (42.86)	29.6817
2010's	4 (57.14)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Dansette, PM; Fontana, E; Poli, SM	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Balani, SK; Gan, LS; Li, P; Lu, C	1
Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

3 review(s) available for diltiazem and raloxifene

Article	Year
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Current drug metabolism, 2005, Volume: 6, Issue:5 Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic	2005
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. Journal of medicinal chemistry, 2012, Jun-14, Volume: 55, Issue:11 Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors	2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

4 other study(ies) available for diltiazem and raloxifene

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:6 Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Microsomes, Liver; Time Factors	2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012